Genmab CEO says Janssen should "show respect" as royalty strife nears conclusion
Danish biotech company Genmab and Johnson & Johnson’s pharmaceutical arm Janssen have been fighting it out over royalty payments for a year. As the verdict draws near, Genmab CEO Jan van de Winkel has taken a jab at Janssen, saying it ought to show Genmab some respect.
by marketwire, translated by daniel pedersen
For around a year, Genmab and its US-based partner Janssen, the pharmaceutical arm of Johnson & Johnson, have been in a legal battle concerning royalty payments from the latter to the Danish biotech company, Danish business daily Børsen reports.